Recombinant adenovirus-p53 enhances the therapeutic effect of surgery and chemoradiotherapy combination in hypopharyngeal squamous cell carcinomas patients

Abstract

The purpose of our study was to assess the safety and efficacy of recombinant adenovirus-p53 (rAd-p53) combined with surgery and chemoradiotherapy (CRT) for patients with hypopharyngeal squamous cell carcinomas (HPSCC). This study retrospectively and consecutively collected clinical data of 102 patients with primary HPSCC who were admitted to the Department of Otolaryngology of West China Hospital, Sichuan University in China between March 2010 and December 2015. A retrospective clinical study of 102 patients with HPSCC was carried out from March 2010 to December 2015. All patients were male and were divided into 3 groups based on the treatments they received, including Single Surgery, Surgery + CRT, and Surgery + CRT + rAd-p53. In the Surgery + CRT + rAd-p53 group, rAd-p53 was intratumorally injected on the 1st day preoperatively; peritumorally injected on the 7th day intraoperatively, and on the 21st, 28th, and 35th days postoperatively. Their clinical data were retrospectively collected and analyzed. In our study, for all 102 patients with HPSCC, 16 patients received Single Surgery, 44 patients received Surgery + CRT therapy, and 42 patients received Surgery + CRT + rAd-p53 therapy. In the Surgery + CRT + rAd-p53 group, all patients could tolerate rAd-p53 treatment and no serious side effect was observed. In addition, rAd-p53 application did not increase the side reactions caused by surgery and CRT. Compared with the 3-year overall survival rates of Single Surgery group and Surgery + CRT group, the 3-year overall survival rates of Surgery + CRT + rAd-p53 group was significantly enhanced (P < .05). Similar results were also observed for the 3-year disease-free survival rates. Our results indicate that rAd-p53 therapy may improve the therapeutic effect of patients with HPSCC, and is a safe and effective treatment method for patients with HPSCC. However, further prospective studies with larger sample sizes are needed to validate our findings.

RETRACTED: Correlation between ER, PR, P53, Ki67 expression, and high-risk HPV infection in patients with different levels of cervical intraepithelial neoplasia

“…Persistent infection of high-risk HPV is also an important factor. [14][15][16] HPV is a common pathogen of female genital tract infection. So far, more than 200 kinds of HPV have been found.…”

A systematic analysis on the clinical safety and efficacy of onco-virotherapy

“… 4 adenovirus 112 advanced unresectable soft-tissue sarcomas, stage 3 49 years, both hyperthermia alone or in combination with radiotherapy TP53 N/A N/A disease control rate better 2018, Liu et al. 59 adenovirus 19 hypopharyngeal squamous cell carcinoma 57.9 years, both surgery alone or in combination with chemo-radiotherapy TP53 N/A 36 overall survival better 2018, ClinicalTrials.gov: NCT01622543 reovirus 310 colorectal cancer, stage 4 50 years, both leucovorin, 5-fluorouracil, oxaliplatin, or bevacizumab N/A N/A 13 progression free survival worse 2018, ClinicalTrials.gov: NCT01619813 reovirus 310 metastatic prostate adeno-carcinoma, stage 4 69 years, male docetaxel and prednisone N/A N/A 20 progression-free survival better 2018, ClinicalTrials.gov: NCT01656538 reovirus 310 metastatic breast cancer, stage 4 44 years, female paclitaxel N/A N/A 295 progression-free survival no change 2018, ClinicalTrials.gov: NCT01708993 reovirus 4.510 on-small cell lung cancer, stage 3-4 63 years, both pemetrexed or docetaxel N/A N/A 27 safety safe 2018, ClinicalTrials.gov: …”

“…Many of the utilized viral vectors were administered in combination with another form of therapy such as chemotherapy, 34 , 40 , 42 , 43 , 57 , 71 , immune checkpoint inhibitors, 13 , 72 , 73 or radiotherapy. 3 , 4 , 32 , 59 Furthermore, most viruses were injected intratumorally and were administered multiple times, which is not surprising, as intratumoral administration of viruses has been shown to be effective. Additionally, multiple injections increase the possibility of inducing stronger antitumor effects and related immune responses.…”

Correlation between ER, PR, P53, Ki67 Expression and High-Risk HPV Infection in Patients with Different Levels of Cervical Intraepithelial Neoplasia

“…The normal expression of p53 protein can induce apoptosis and cause cell cycle block. p53 protein mutations can lead to cell transformation and over-proliferation and tumor behavior [12,13] . This paper specifically discusses the expression of ER, PR, p53, Ki67 and the correlation of HPV infection in patients with different levels of cervical squamous epithelial lesions.…”